Skip to Main content Skip to Navigation
Journal articles

Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response

Abstract : Non-Hodgkin lymphoma (NHL) is one of the most common malignancies and a major cause of morbidityand mortality. Radioimmunotherapy (RIT) is a novel modality for treating NHL which offers the combineduse of monoclonal antibodies for specific targeting of malignant cells and radiation for killing these cells.Despite the promising results favoring RIT in several clinical studies in different target populations andNHL types, Food and Drug Administration (FDA) approval for RIT agents is restricted to a limited numberof indications and agents, maybe because of several ambiguities that still exist in the field. One of theseambiguities are the lack of evidence-based prognostic factors that determine what patient populationwould benefit most from RIT, which is essential to know in order to optimize the efficacy and safetyof treatment with RIT. As well as selecting the best patient population for RIT, it is important to assessthe response to RIT in order to provide further treatment strategies or avoid unnecessary therapies anddiagnostic procedures. In this review we have explored the details of how to predict the efficiency of RIT∗
Document type :
Journal articles
Complete list of metadatas

Cited literature [79 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01414377
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, December 12, 2016 - 11:47:02 AM
Last modification on : Friday, June 19, 2020 - 3:08:49 AM
Long-term archiving on: : Monday, March 27, 2017 - 4:21:06 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Mahsa Eskian, Mirhojjat Khorasanizadeh, Francoise Kraeber-Bodere, Nima Rezaei. Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response. Critical Reviews in Oncology/Hematology, Elsevier, 2016, 107, pp.182 - 189. ⟨10.1016/j.critrevonc.2016.10.005⟩. ⟨inserm-01414377⟩

Share

Metrics

Record views

143